latest news releases from the newsroom
Shionogi Extends Research Partnership With MorphoSys
MARTINSRIED, Germany, Sept. 29, 2008 (GLOBE NEWSWIRE) -- MorphoSys AG (Frankfurt:MOR) (Prime Standard Segment:TecDAX) announced today that Shionogi & Co., Ltd., Osaka, Japan, has elected to extend its current license agreement covering the use of MorphoSys's HuCAL technology in drug discovery, for three additional years. Under the terms of the agreement, Shionogi will continue to have the right to use MorphoSys's proprietary antibody library HuCAL GOLD for research purposes at one of its research sites. MorphoSys will receive annual user fees from Shionogi for access to the HuCAL technology. Further financial details were not disclosed.
Venture Capital Investments Forging Ahead Despite Exit Slowdown, According to PricewaterhouseCoopers LLP
NEW YORK, Sept. 29, 2008 (GLOBE NEWSWIRE) -- According to a new study released today from PricewaterhouseCoopers LLP, the venture capital-backed IPO market is at a 30-year low, with the second quarter of 2008 marking the first time since 1978 that there have been zero venture capital-backed IPO's in a given quarter. The report, entitled "The Exit Slowdown and the New Venture Capital Landscape," discusses the current state of the IPO market and the trends and resulting impact this IPO slowdown could have on the venture capital (VC) industry. It includes data from the MoneyTree Report, a quarterly survey that tracks cash-for-equity investments by the professional VC community in private, emerging companies in the United States. The MoneyTree Report is produced by PricewaterhouseCoopers LLP and the National Venture Capital Association, based on data from Thomson Reuters.